专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190203192A1 KLK6-MEDIATED CNS-SPECIFIC ANTIBODY PRODRUG ACTIVATION 审中-公开
公开(公告)号：US20190203192A1
公开(公告)日：2019-07-04
申请号：US15859500
申请日：2017-12-30
申请人： Development Center for Biotechnology
发明人： Jei-Hwa YU , Iok-U FONG , Su-Yi HSU , Chih-Yung HU , Chia-Cheng WU
IPC分类号： C12N9/64 , C07K16/22 , C07K14/575 , C07K16/28 , A61P25/00 , A61P35/00 , A61P37/02 , A61P31/00
CPC分类号： C12N9/6445 , A61K39/395 , A61K2039/505 , A61P25/00 , A61P31/00 , A61P35/00 , A61P37/02 , C07K14/5759 , C07K16/22 , C07K16/2803 , C07K16/46 , C07K2317/24 , C07K2317/55 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： An antibody prodrug capable of being selectively activated in a central nervous system (CNS) by protease KLK6 includes an antibody for treating a disease or disorder in the CNS; a KLK6 cleavable peptide fused to an N-terminus of a heavy chain and/or a light chain of the antibody; and a blocker fused to an N-terminus of the KLK6 cleavable peptide. The disease or disorder is a cancer, inflammatory disease, autoimmune disease, infectious disease, or neuron degeneration disease.

2. 发明申请

US20180088134A1 Compilation of Detection Reagents, In-Vitro Method for Detecting Mutated Leptin, and Use of a Detection Reagent 审中-公开
公开(公告)号：US20180088134A1
公开(公告)日：2018-03-29
申请号：US15558322
申请日：2015-12-23
申请人： Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH
发明人： Bertram Flehmig
IPC分类号： G01N33/74
CPC分类号： G01N33/74 , C07K14/5759 , G01N2800/044
摘要： The invention relates to a compilation of detection reagents, wherein the compilation comprises a first and a second detection reagent, wherein the first detection reagent binds non-mutated leptin with a first binding value, but does not bind mutated leptin or binds it with a maximum of 50% of the binding value of non-mutated leptin, and wherein the second detection reagent binds both mutated and non-mutated leptin with a second binding value. The invention furthermore relates to an in-vitro method for detecting mutated leptin and the use of a detection reagent.

3. 发明申请

US20170082620A1 C1q-ADIPONECTIN COMPLEX AND USE THEREOF 审中-公开
公开(公告)号：US20170082620A1
公开(公告)日：2017-03-23
申请号：US15368520
申请日：2016-12-02
申请人： OSAKA UNIVERSITY , OTSUKA PHARMACEUTICAL CO., LTD.
发明人： Iichiro SHIMOMURA , Tohru FUNAHASHI , Ken KISHIDA , Hironori KOBAYASHI , Shigeo TAKAHASHI
IPC分类号： G01N33/564 , G01N33/68 , G01N33/74
CPC分类号： G01N33/564 , C07K14/472 , C07K14/5759 , G01N33/6893 , G01N33/74 , G01N2333/4716 , G01N2800/04 , G01N2800/323
摘要： An object of the present invention is to provide a biomarker that can be used as a precise diagnostic marker for MetS or arteriosclerosis risk.The present invention provides a C1q-adiponectin complex comprising naturally occurring adiponectin and C1q.

4. 发明申请

US20160207974A1 ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY 有权
标题翻译：具有增强作用时间和降低免疫原性的工程多糖
公开(公告)号：US20160207974A1
公开(公告)日：2016-07-21
申请号：US14837705
申请日：2015-08-27
申请人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Caroline Ekblad , Jonathan D. Roth
发明人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Caroline Ekblad , Jonathan D. Roth
IPC分类号： C07K14/575 , C07K14/315
CPC分类号： C07K14/5759 , A61K38/00 , A61K38/22 , A61K38/2264 , C07K14/315 , C07K14/575 , C07K2319/31 , C07K2319/70
摘要： Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
摘要翻译：提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括每周给药一次。所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。还提供了包括脂肪营养不良，血脂异常，高脂血症，超重，肥胖，下丘脑闭经，阿尔茨海默病，瘦素缺乏症，脂肪肝疾病或糖尿病（包括I型和II型）的疾病和病症的药物组合物和治疗方法。可以通过本文所述的化合物和方法治疗的其它疾病和病症包括非酒精性脂肪性肝炎（NASH）和非酒精性脂肪性肝病（NAFLD），代谢综合征X和亨廷顿氏病。

5. 发明申请

US20160137709A1 ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION 审中-公开
公开(公告)号：US20160137709A1
公开(公告)日：2016-05-19
申请号：US14800537
申请日：2015-07-15
申请人： AEGERION PHARMACEUTICALS, INC.
发明人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Jonathan David Roth
IPC分类号： C07K14/575 , C07K14/00
CPC分类号： C07K14/5759 , A61K38/00 , A61K38/2264 , C07K14/00 , C07K14/575 , C07K2319/33
摘要： Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.

6. 发明申请

US20150376264A1 BOVINE FUSION ANTIBODIES 审中-公开
标题翻译： BOVINE融合抗体
公开(公告)号：US20150376264A1
公开(公告)日：2015-12-31
申请号：US14760115
申请日：2014-01-10
申请人： THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
发明人： Feng WANG , Yong ZHANG , Peter G. SCHULTZ
IPC分类号： C07K16/00 , C07K7/08 , C07K14/64 , C07K14/81 , C07K14/575 , C07K14/61
CPC分类号： C07K16/00 , C07K7/08 , C07K14/575 , C07K14/5759 , C07K14/605 , C07K14/61 , C07K14/635 , C07K14/64 , C07K14/811 , C07K16/2869 , C07K2317/565 , C07K2318/10 , C07K2319/00 , C07K2319/30
摘要： Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
摘要翻译：本文公开了包含至少一个免疫球蛋白结构域或其片段的免疫球蛋白构建体; 以及连接到或插入所述免疫球蛋白结构域的治疗性多肽或其衍生物或变体。还提供了包含哺乳动物免疫球蛋白重链的免疫球蛋白构建体，其包含互补决定区3（CDR3H）或其片段中的至少一部分旋钮结构域; 和连接到CDR3H或插入到CDR3H中的治疗性多肽。还提供了包含哺乳动物免疫球蛋白重链的免疫球蛋白构建体，其包含互补决定区3（CDR3H）或其片段中的至少一部分茎结构域; 以及与CDR3H的所述茎结构域连接或插入的治疗性多肽。本文还描述了包含本文所述的用于治疗和预防受试者的疾病或病症的免疫球蛋白构建体的方法和组合物。

7. 发明授权

US09221896B2 Albumin fusion proteins 有权
公开(公告)号：US09221896B2
公开(公告)日：2015-12-29
申请号：US14611810
申请日：2015-02-02
申请人： Human Genome Sciences, Inc.
发明人： Craig A. Rosen , William A. Haseltine , Steven M. Ruben
IPC分类号： C07K14/00 , A61K38/28 , A61K38/00 , A61P3/10 , A61K38/31 , C07K14/765 , A61K38/04 , A61K38/17 , C07K14/47 , C07K14/505 , C07K14/575 , C07K14/635 , C12N15/62 , A61K47/48 , C07K14/62 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , C07K14/435 , C07K14/475 , C07K14/50 , C07K14/51 , C07K14/52 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/55 , C07K14/56 , C07K14/565 , C07K14/585 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/82 , C07K16/26 , C12N9/04
CPC分类号： C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

8. 发明授权

US09181561B2 Adiponectin-containing eating behavior control agent for oral administration 有权
标题翻译：含脂连蛋白的饮食行为控制剂用于口服
公开(公告)号：US09181561B2
公开(公告)日：2015-11-10
申请号：US13146575
申请日：2010-01-18
申请人： Takeshi Matsumura , Rie Yasuno , Chihiro Sugimoto , Noriko Tabayashi , Uiko Kagaya , Hiroko Miyashiro
发明人： Takeshi Matsumura , Rie Yasuno , Chihiro Sugimoto , Noriko Tabayashi , Uiko Kagaya , Hiroko Miyashiro
IPC分类号： C12N15/16 , A23L1/305 , A61K38/22 , A01H5/08 , C07K14/475 , C12N15/82 , C07K14/575
CPC分类号： C12N15/8257 , A23L33/17 , A23L33/18 , A61K38/22 , C07K14/5759
摘要： Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.
摘要翻译：公开了一种能够大量口服摄取脂联素的技术，能够扩大脂连蛋白的使用范围。具体公开了口服给药的食欲调节剂，其包含脂联素作为活性成分。特别地，食欲控制剂包括能够表达脂联素的转化体。还具体公开了用于控制食欲的食物组合物，其包含食欲控制剂。

9. 发明申请

US20150031864A1 Modified Adiponectin Polypeptides and Their Uses 审中-公开
标题翻译：改性脂连蛋白多肽及其用途
公开(公告)号：US20150031864A1
公开(公告)日：2015-01-29
申请号：US14381189
申请日：2013-02-27
申请人： Ambrx, Inc.
发明人： Vadim Kraynov , Anna-Maria A. Putnam
IPC分类号： C07K14/575
CPC分类号： C07K14/575 , A61K38/00 , C07K14/5759
摘要： Modified adiponectin polypeptides and uses thereof are provided.
摘要翻译：提供了改良的脂连蛋白多肽及其用途。

10. 发明申请

US20140194343A1 CTRP6 WHICH CAN BE USED AS THERAPEUTIC AND PROPHYLACTIC AGENT FOR AUTOIMMUNE DISEASES 有权
标题翻译： CTRP6可作为治疗自身免疫性疾病的治疗剂和预防剂
公开(公告)号：US20140194343A1
公开(公告)日：2014-07-10
申请号：US14116039
申请日：2012-05-09
申请人： Yoichiro Iwakura , Masanori Murayama , Harumichi Ishigame , Shigeru Kakuta
发明人： Yoichiro Iwakura , Masanori Murayama , Harumichi Ishigame , Shigeru Kakuta
IPC分类号： C07K14/47
CPC分类号： C07K14/47 , A61K38/1709 , C07K14/5759 , Y02A50/411
摘要： [Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application.[Solution] A pharmaceutical composition containing CTRP6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided.
摘要翻译： [问题]本发明的目的是阐明CTRP6的生物学功能及其应用。 [溶液]含有CTRP6用于预防或治疗自身免疫性疾病的药物组合物。理想地，提供了用于预防或治疗与自身免疫疾病相关的炎症，例如类风湿性关节炎或1型糖尿病的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式